Genmab (GMAB) said Tuesday that Q3 worldwide net sales of DARZALEX, including its subcutaneous formulation, totaled $4.24 billion, as reported by Johnson & Johnson (JNJ).
It said U.S. sales reached $2.53 billion, while sales in the rest of the world were $1.71 billion.
Genmab said it receives royalties on worldwide net sales of both intravenous and subcutaneous formulations under its exclusive global licensing agreement with J&J for the development, manufacturing and commercialization of daratumumab.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments